2. TB Magnitude
▪ TB: 9th leading cause of death worldwide
▪ Leading cause from a single infectious agent, ranking above HIV/AIDS
▪ ≈1.3 million deaths in HIV-ve / 374 000 in HIV+ve people (2016)
8/20/2018
2
4. MDR Problem Statement : Globally
▪ 5% of total TB cases, 3.9% of new cases, 21 % of previously Rx cases
▪ 490,000 estimated (2016)
▪ ++ 110 000 susceptible to INH but resistant to rifampicin (2016)
▪ 47% of global MDR burden in China, India & Russian Federation
▪ ≈ 9.5% of MDR-TB cases have additional DR (XDR-TB).
▪ 117 countries worldwide have reported at least one XDR-TB case
8/20/2018
04
5. Global response
Burden
• 490 000 people fell ill with MDR-TB in 2016
• Additional 110 000 people with RR TB requiring 2nd-line Rx
Detection
• 132000 cases of MDR TB detected
Treatment
• 125000 started on MDR TB RX
Outcome
• 52% Successful outcome
8/20/2018
05
6. MDR Problem Statement: India
▪ Prevalence of Rifampicin (R) & MDR-TB in India is around 1,47,000
▪ Translates to around 11 patients/lac population annually
▪ RNTCP Dx & initiated Rx in 34016 MDR-TB & 2476 XDR-TB cases (2016)
▪ 46% had successful Rx outcome
8/20/2018
06
7. 1st National Anti-TB drug resistance survey (NDRS)
▪ NDRS concluded recently 2014-16
▪ 526 (92.5%) DMCs participated
▪ Quality of specimens collected was good with >97% specimens accepted
▪ 95% patient enrolments were completed within the planned period
▪ Recovery rate for cultures was 94.6% in new & 92.8% in previously Rx pts
8/20/2018
07
11. Case Definition
Presumptive DR TB:
Failed Rx with 1st line drugs
Pediatric Non responders
Contacts of DR TB
TB Pts found +ve on f/u sputum exam
Previously Rx TB cases
TB-HIV Co-infection
8/20/2018
11
12. RNTCP Criteria – MDR TB
▪ A new smear (+) pt. remaining smear (+) at end of 5th month
▪ A new smear (-) pt. becoming smear (+) at the end of 5th month
▪ A pt. Rx with regimen for previously Rx remaining (+) at 4th month
▪ Smear (+) contacts of an established / confirmed MDR-TB case
8/20/2018
12
13. Classification on Drug Resistance
▪ MR : Resistance to one 1st line ATB drug only
▪ PDR : Resistance to > one 1st line ATB drug (except both H & R)
▪ MDR : Resistance to at least both H & R
▪ RR : Resistance to R (pheno/genotypic method) with/without
resistance to other drugs excluding H
▪ XDR : MDR plus FQ resistance plus 2nd line injectable resistance
8/20/2018
13
15. Diagnosis
▪ Lab based
Phenotypic DST (Solid/liquid culture)
OR
Genotypic (LPA/CBNAAT- RNTCP)
CBNAAT: R LPA: H & R
Genotypic faster; not growth based
DST (LJ): 84 days Liq C (MGIT): 42 days LPA: 72 hrs CBNAAT: 2 hrs
8/20/2018
015
16. Diagnosis contd…..
▪ CBNAAT: Single specimen LPA: Two samples
▪ Wherever facilities available; DST of all drugs intended for regimen
▪ If RR by CBNAAT/LPA
Liq C DST at base line for Levo, Moxi, Kana, Capreo, Ethambutol &
Ethionamide, Linezolid, Pyrazinamide
plus
LPA for INH on sample/culture isolate to decide on INH use
8/20/2018
16
17. Diagnosis contd…..
▪ If R sensitive (CBNAAT) in presumptive DR-TB cases, samples for LPA/Liq C
▪ INH sensitive Pts. after LPA testing OR awaiting LPA results should continue Rx
▪ If INH Resistance by LPA,
Report must mention KAT G or INH-A mutation
&
Liq C DST for E, Z, Kana, Levo
If resistance to 2nd line injectables/FQs; DST for remaining 2nd line drugs
Initiate/Modify Rx as per DST results
8/20/2018
17
26. Shorter MDR-TB Rx Regimen
Recommended for patients in whom the diagnosis of
▪ MDR/RR-TB has been reliably confirmed by molecular (e.g. CBNAAT/
LPA) or phenotypic DST method
▪ And are found to be sensitive to both FQ and SLI by SL-LPA
▪ Children & PLHIV on ART could receive the shorter MDR-TB regimen
▪ Standardized shorter MDR-TB regimen with 7 drugs & a Rx duration of
9- 11 months
8/20/2018
26
27. Shorter MDR-TB Rx Regimen contd…..
▪ Total duration is 9-11 months, depending on IP duration
▪ IP should be given for at least 4 months
▪ After 4th month of Rx, if the result of sputum microscopy is -ve then
CP should be initiated
▪ If sputum smear doesn’t become microscopy -ve by the 4th month of
Rx, IP should be prolonged till smear conversion
▪ If IP is prolonged, the injectable agent is only given 3 times/week.
▪ IP should be extended for a max of 2 months (IP is not > 6 months)
▪ Duration of CP is fixed for 5 months
8/20/2018
27
28. XDR-TB Rx Regimen
▪ Total duration would be of 24-30 months duration with 6-12 months
IP & 18 months CP
▪ The change from IP to CP will be done only after achievement of
culture conversion
▪ IP can be extended on monthly basis from 6 months up to a max of 12
months
8/20/2018
28
29. Management of Contacts of DR TB
▪ People living in same household as index pt. or spending many hours/day
together with pt. in same indoor space
▪ Should be identified through contact tracing & evaluated for active TB
▪ If contact is found to be suffering from PTB disease irrespective of smear
based MB, s/he will be identified as a Presumptive DR-TB
▪ Initiated on regimen for new/previously Rx pt. based on their previous history
▪ If pt. is confirmed as having DRTB, appropriate DR-TB Rx must be initiated
8/20/2018
29
30. Newer Anti MDR TB Drugs
▪ Bedaquiline: Blocks an enzyme inside MTB bacteria called ATP
synthase
▪ Recommended dose is 400 mg /day for 2 weeks & then 200 mg taken
3 times/week (with at least 48 hours b/w doses)
▪ Side effects are headache, dizziness, malaise, joint pain, QT
prolongation & increases in liver enzymes
8/20/2018
30
31. Newer Anti MDR TB Drugs contd…..
▪ Delamanid: Dihydro-nitroimidazooxazole derivative; inhibits synthesis
of cell wall components, methoxy mycolic acid & ketomycolic acid
▪ Dose: 100 mg/day
▪ Side effects are nausea, vomiting and dizziness. Anxiety, pins &
needles, shaking and QT prolongation
8/20/2018
31
34. Follow up
▪ Microbiological: One sputum specimen to be collected & examined
by Cx at least 30 days apart from 3rd to 7th month of Rx (end of
months 3,4,5,6,7) & at 3 monthly intervals from 9th month onward till
completion of Rx (9,12,15,18,21,24).
If any Cx during CP or end of Rx is +ve then it should be followed by
monthly Cx for 3 months
Weight: Monthly
Chest X ray: At the end of IP, end of Rx & whenever clinically indicated
Physical Evaluation: Every month for 6 months then every 3 months
for 2 years
8/20/2018
34
35. Follow up contd…..
▪ S. creatinine: Monthly for first 3 months then every 3 months during
injectable phase
▪ CBC: Weekly in first month, then monthly to rule out bone marrow
suppression
▪ LFT: Monthly in IP & 3 monthly during CP
8/20/2018
35
36. Extension of Treatment
▪ IP can be extended for max. 3 months (max IP duration-9 months)
▪ In all MDR TB cases with additional DR (including XDR TB), IP can be
extended for max. 6 months (max IP duration-12 months)
8/20/2018
36
37. Role of surgery in MDR-TB
When U/L resectable disease is present, surgery can be considered for
▪ Absence of clinical/MB response to therapy despite 6-9 months of Rx
▪ High risk of failure/relapse due to high degree of resistance/extensive
parenchymal involvement
▪ Morbid complications like haemoptysis, brochiectasis, empyema
▪ Recurrence of +ve culture status during Rx course
▪ Relapse after completion of ATT
8/20/2018
37
38. Treatment Outcomes in M/XDR TB
Interim outcomes
▪ Culture conversion: Pt. is considered to have Cx converted when 2
consecutive Cx, taken at least 30 days apart, are found to be -ve.
Specimen collection date of 1st -ve Cx is used as date of conversion
▪ Culture reversion: Pt. is considered to have Cx reverted when, after an
initial Cx conversion, 2 consecutive Cx, taken at least 30 days apart,
are found to be +ve. For purpose of defining Rx failed, reversion is
considered only when it occurs in CP
8/20/2018
38
39. Treatment outcomes in M/XDR TB contd…..
Final Outcomes
▪ Cured: Rx completed without evidence of failure AND ≥ 3 consecutive
Cx taken at least 30 days apart are –ve after IP
▪ Treatment completed: A patient who has completed Rx according to
guidelines but doesn’t meet definition for cure/failure due to lack of
bacteriological results
▪ Treatment success: Cured + Rx Completed
▪ Treatment failure: Lack of microbiological conversion by end of IP,
reversion in CP, evidence of acquired resistance to FQs/SLID or ADRxn
8/20/2018
39
40. Treatment Support Program
▪ Include initial & f/u counselling, supervision of Rx, additional
nutritional support, screening of ADR, co-morbidity management
▪ Compensation is provided for transport costs incurred by DR TB
patient for sending specimen for f/u or for travel to DR TB centre
▪ MDR TB Rx supporters get 5000/case for ensuring Rx completion
8/20/2018 40
42. Drug Resistant TB Centre
▪ 147 DR-TBCs across India (2017), 1/10 million population, including
some private institutes
▪ 5-10 districts attached to each centre
▪ DR-TB pts. admitted for a short period & once stabilized on Rx
discharged & referred back to their districts for continuation &
completion of Rx
▪ Pts. are referred back to DR-TBCs for change of regimens/ ADR Mx
8/20/2018
42
43. ▪ Since March 2016, 500 CBNAAT machines have been made functional
in addition to 128 existing machines to cover access to most of
districts in India
▪ These machines are currently utilized at district level for testing
presumptive DR-TB patients & presumptive TB patients among key
populations to detect presence of M. Tb in the biological specimen
with concomitant detection of RR-TB if present.
▪ A 35% rise in MDR/ RRTB patients notified was observed in Q2 2016
against Q1 2016 which is expected to further increase in future
8/20/2018 43
44. National Strategic Plan (2017-25) and PMDT
Objectives
▪ By 2017, complete nationwide geographical coverage of access to
baseline 2nd line DST using SL-LPA, access to shorter MDR-TB regimen
and newer drugs like Bedaquiline
▪ By 2025 ensure Universal access to rapid molecular DRT for all Dx TB
patients; Universal access to DST guided Rx expands access to newer
drugs; and management of NTM
8/20/2018
44
46. Strategies for Drug Resistant TB
8/20/2018
046
Strategies
for DRTB
Control
Prevention
of DRTB
DST
guided
Rx
NDR
Survey
Newer
Regimen
Improving
adherence &
Counselling
Nutritional
Assessment
& Sx
Strengthening
procurement
of SLD
47. References
RNTCP Guidelines Programmatic Management of Drug Resistant TB 2017
RNTCP Technical and operational guidelines of TB control in India 2016
National strategic plan for TB elimination 2017–2025
TB India 2017 RNTCP Annual Status Report
WHO Global TB report 2017
WHO MDR TB update 2016
8/20/2018
47
51. Rx success with shorter MDR-TB regimen vs
conventional MDR-TB regimens
8/20/2018
51
52. MDR TB with mixed pattern of resistance
8/20/2018
52
53. MDR TB/RR TB (without additional resistance)
8/20/2018
53
All MDR TB isolates to be subjected to LC DST at baseline for kanamycin &
Levofloxacin, the results of which are available after 6-8 wks, additional modifications
to be made accordingly